lirodegimod

KT-333 (lirodegimod) is a first-in-class, potent, highly selective heterobifunctional small molecule degrader of the signal transducer and activator of transcription 3 (STAT3) protein. Developed by Kymera Therapeutics, it is administered intravenously and designed to induce targeted degradation of STAT3 via the ubiquitin-proteasome system by binding both STAT3 and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). Aberrant activation of STAT3 is implicated in various hematological malignancies—including cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), classic Hodgkin lymphoma—as well as solid tumors. By degrading STAT3, KT-333 disrupts tumor cell survival pathways and immune evasion mechanisms. The drug has demonstrated robust pharmacodynamic effects with high levels of STAT3 degradation in clinical trials and has shown antitumor activity across multiple cancer types[1][2][4][5][7][8].

Other names

lirodegimod